Response Biomedical (RPBIF)

Response Biomedical Corp. was incorporated on August 20, 1980. The Company develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP platform for clinical and environmental applications. RAMP represents a paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use. The Company develops, manufactures and sells the RAMP system for the medical point of care market including cardiovascular tests and infectious disease tests, and the on-site environmental testing market including biodefense and vector infectious disease testing. The Company's products are subject to a variety of government regulation (federal, state and municipal) both within the United States and in other international jurisdictions. RAMP system is a proprietary platform technology that combines a sensitive fluorescence detection system with simple lateral flow immunoassays. Although lateral flow immunoassay technology has been available for over 25 years, the market for early generation rapid immunoassays has been limited by their inability to provide the accurate, quantitative results required by the majority of test situations. RAMP maintains the key positive attributes of lateral flow immunoassays - simplicity, specificity, reliability and rapid results, while adding a unique, patented feature that can improve test performance versus other companies' traditional lateral flow systems. RAMP system also has a second "control zone". The Company also formed a newly created wholly owned subsidiary in the U.S. (Response Point of Care Inc.) and opened Regional Offices in Charlotte, N.C., U.S.A. and Shanghai, China to facilitate and enhance the truly global nature of Response. In addition to the Corporate Office in Vancouver, Canada, the regional offices will strengthen and support Response's extensive Global Distribution Network.